Adaptive Biotechnologies (NASDAQ:ADPT) Insider Harlan Robins Sells 10,000 Shares of Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Harlan Robins sold 10,000 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $15.72, for a total value of $157,200.00. Following the completion of the transaction, the insider directly owned 1,169,524 shares in the company, valued at $18,384,917.28. The trade was a 0.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Adaptive Biotechnologies Stock Performance

Shares of NASDAQ ADPT traded down $0.32 during midday trading on Thursday, hitting $16.12. 212,915 shares of the company’s stock traded hands, compared to its average volume of 1,844,309. The firm has a fifty day moving average of $16.85 and a 200 day moving average of $15.79. Adaptive Biotechnologies Corporation has a 1 year low of $6.26 and a 1 year high of $20.76. The stock has a market capitalization of $2.48 billion, a price-to-earnings ratio of -40.30 and a beta of 2.19.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The company had revenue of $71.68 million for the quarter, compared to the consensus estimate of $59.38 million. During the same quarter last year, the firm posted ($0.23) earnings per share. The firm’s revenue was up 51.0% compared to the same quarter last year. On average, equities analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.

Hedge Funds Weigh In On Adaptive Biotechnologies

Hedge funds have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd bought a new stake in Adaptive Biotechnologies during the 4th quarter valued at approximately $28,000. Sound Income Strategies LLC bought a new position in Adaptive Biotechnologies in the 3rd quarter worth approximately $30,000. EverSource Wealth Advisors LLC grew its holdings in Adaptive Biotechnologies by 197.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after buying an additional 1,565 shares in the last quarter. Assetmark Inc. raised its position in shares of Adaptive Biotechnologies by 867.9% during the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after buying an additional 2,708 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. purchased a new position in shares of Adaptive Biotechnologies in the fourth quarter worth $51,000. Institutional investors own 99.17% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on ADPT. BTIG Research raised their target price on Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 21st. JPMorgan Chase & Co. raised their price objective on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Friday, February 6th. Piper Sandler set a $21.00 price objective on Adaptive Biotechnologies in a research note on Friday, February 6th. Finally, Morgan Stanley started coverage on shares of Adaptive Biotechnologies in a research note on Monday, December 1st. They set an “equal weight” rating and a $21.00 target price on the stock. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $18.25.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.